Table 2.

Treatment, follow-up, complications and sequelae.

IV antibiotics Cephalosporins–no. (%) Linezolid–no. (%) Glycopeptides–no. (%) Aminoglycosides–no. (%) Meropenem–no. (%) Amoxicillin-clavulanate–no. (%) Rifampicin–no. (%) Quinolones–no. (%) Fosfomycin–no. (%)	219 (68.7) 112 (35.1) 103 (32.3) 77 (24.1) 35 (11.0) 33 (10.3) 25 (7.8) 20 (6.3) 13 (4.1)
OS antibiotics Quinolones–no. (%) Linezolid–no. (%) Amoxicillin-clavulanate–no. (%) Cephalosporins–no. (%) Rifampicin–no. (%) Clindamycin–no. (%) IREP–no. (%) Glycopeptides–no. (%)	123 (38.6) 79 (24.8) 75 (23.5) 43 (13.5) 17 (5.3) 7 (2.2) 7 (2.2) 6 (1.9)
IV therapy (days)–median (range)  < 14 days–no. (%)  > 14 days–no. (%) OS therapy (days)–median (range)  < 14 days–no. (%)  > 14 days–no. (%) Total antibiotic therapy (days)–median (range)  < 6 weeks–no. (%)  > 6 weeks–no. (%)	21 (14–29) 58 (18.2) 261 (81.8) 16 (12–24.5) 92 (28.8) 227 (71.2) 42 (31–49) 305 (95.6) 12 (3.8)
Local complications Soft-tissue abscess–no. (%) Perilesional cellulitis–no. (%) Myositis–no. (%) Bone sequestration–no. (%)	139 (43.6) 118 (37) 67 (21.0) 40 (12.5)
Surgical intervention Curettage–no. (%) Arthrocentesis–no. (%) Osteosynthesis–no. (%)	40 (12.5) 11 (3.4) 12 (3.8)
Hospitalization (days)–median (Q1-Q3)	22.5 (16–31)
Follow-up–median; Q1–Q3 (range)	8; 4–14 (0–60)
Relapse–no. (%)	17 (5.3)
Sequelae–no. (%)	43 (13.5)
Chronic osteomyelitis–no. (%)	45 (14.1)